Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Treatment with biological agents has become standard of care in treatment of immune-mediated diseases (IMD), including rheumatoid arthritis and psoriatic arthritis. Yet, a significant proportion of patients experience loss of response to biologics, need treatment escalation, or develop side effects....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rambam Health Care Campus
2023-04-01
|
| Series: | Rambam Maimonides Medical Journal |
| Subjects: | |
| Online Access: | https://www.rmmj.org.il/issues/57/1618/manuscript |
| _version_ | 1797836186276855808 |
|---|---|
| author | Victoria Furer Ori Elkayam |
| author_facet | Victoria Furer Ori Elkayam |
| author_sort | Victoria Furer |
| collection | DOAJ |
| description | Treatment with biological agents has become standard of care in treatment of immune-mediated diseases (IMD), including rheumatoid arthritis and psoriatic arthritis. Yet, a significant proportion of patients experience loss of response to biologics, need treatment escalation, or develop side effects. During the past decade, new biologic agents with different targeted molecular pathways have been approved for treatment of IMD, introducing the possibility of concomitant dual biologic therapy. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field of IMD, addressing the unmet clinical need of patients with refractory diseases and treatment of comorbidities, such as osteoporosis, asthma, atopic dermatitis, and urticaria. Despite the increasing use of biologics as a dual therapy across different indications, there is a paucity of data concerning the safety of the simultaneous use of more than one biological agents. The purpose of this review is to summarize the current literature on the use of dual biologics in patients with rheumatoid arthritis and psoriatic arthritis, addressing the potential adverse effects associated with combination therapy, and highlighting future directions in the use of this novel therapeutic modality. |
| first_indexed | 2024-04-09T15:04:38Z |
| format | Article |
| id | doaj.art-f4915d821a944eb6b151156311a1ef9a |
| institution | Directory Open Access Journal |
| issn | 2076-9172 |
| language | English |
| last_indexed | 2024-04-09T15:04:38Z |
| publishDate | 2023-04-01 |
| publisher | Rambam Health Care Campus |
| record_format | Article |
| series | Rambam Maimonides Medical Journal |
| spelling | doaj.art-f4915d821a944eb6b151156311a1ef9a2023-04-30T17:40:28ZengRambam Health Care CampusRambam Maimonides Medical Journal2076-91722023-04-01142e000710.5041/RMMJ.10494Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic ArthritisVictoria Furer0Ori Elkayam1Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelTreatment with biological agents has become standard of care in treatment of immune-mediated diseases (IMD), including rheumatoid arthritis and psoriatic arthritis. Yet, a significant proportion of patients experience loss of response to biologics, need treatment escalation, or develop side effects. During the past decade, new biologic agents with different targeted molecular pathways have been approved for treatment of IMD, introducing the possibility of concomitant dual biologic therapy. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field of IMD, addressing the unmet clinical need of patients with refractory diseases and treatment of comorbidities, such as osteoporosis, asthma, atopic dermatitis, and urticaria. Despite the increasing use of biologics as a dual therapy across different indications, there is a paucity of data concerning the safety of the simultaneous use of more than one biological agents. The purpose of this review is to summarize the current literature on the use of dual biologics in patients with rheumatoid arthritis and psoriatic arthritis, addressing the potential adverse effects associated with combination therapy, and highlighting future directions in the use of this novel therapeutic modality.https://www.rmmj.org.il/issues/57/1618/manuscriptbiological drugsdual biological therapyrheumatoid arthritispsoriatic arthritissafety |
| spellingShingle | Victoria Furer Ori Elkayam Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Rambam Maimonides Medical Journal biological drugs dual biological therapy rheumatoid arthritis psoriatic arthritis safety |
| title | Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis |
| title_full | Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis |
| title_fullStr | Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis |
| title_full_unstemmed | Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis |
| title_short | Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis |
| title_sort | dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis |
| topic | biological drugs dual biological therapy rheumatoid arthritis psoriatic arthritis safety |
| url | https://www.rmmj.org.il/issues/57/1618/manuscript |
| work_keys_str_mv | AT victoriafurer dualbiologictherapyinpatientswithrheumatoidarthritisandpsoriaticarthritis AT orielkayam dualbiologictherapyinpatientswithrheumatoidarthritisandpsoriaticarthritis |